Top

Published in:

01-10-2004 | Original Research Article

The effects of pharmaceutical consumption and obesity on the quality of life in the Organization of Economic Cooperation and Development (OECD) countries

Authors: H. E. Frech III, Richard D. Miller Jr

Published in: PharmacoEconomics | Special Issue 2/2004

Abstract

Objective: The objective of this study is to validate our earlier work on life expectancy with more recent data and, more importantly, to extend it to examine quality of life, not only the length of life.

Design and setting: The analysis focuses on the production of health, disaggregating healthcare into pharmaceutical consumption and other healthcare. Going beyond our earlier work, measures of health include life expectancy and disability-adjusted life expectancy (DALE). Also, we consider the impact of obesity. The sample was 18 Organization of Economic Cooperation and Development (OECD) countries. The measure of pharmaceutical consumption is the best that is available for these countries.

Main outcome measures and results: Confirming our earlier work, pharmaceutical consumption has a positive and statistically significant effect on life expectancy at 40 and 60 years (significant at the 0.05 level, based on a two-tailed test). The effects are slightly larger than in the earlier work. Turning to DALE, pharmaceutical consumption has a positive and statistically significant effect at birth and at 60 years (significant at the 0.05 and 0.01 levels, respectively), based on a two-tailed test. The effects on DALE are larger than the effects on life expectancy.

Conclusions: Increased pharmaceutical consumption helps improve quality of life, as well as life expectancy.

Miller Jr RD, HE Frech III. Health care matters: pharmaceuticals, obesity, and the quality of life. Washington, DC: The AEI Press 2004. Also available from URL: http://www.aei.org/book757 [Accessed August 2004]

Miller Jr RD, HE Frech III. Is There a link between pharmaceutical consumption and improved health in OECD countries? Pharmacoeconomics 2000; 18 Suppl. 1: 33–45CrossRef

Frech III HE, Miller Jr RD. The productivity of health care and pharmaceuticals: an international comparison. Washington, DC: The AEI Press, 1999

Comanor WS, Frech III HE, Miller Jr RD. Is the United States an outlier in health care and health outcomes? A preliminary analysis. In: Komlos J, editor. Health and Economic Policy. Cambridge (MA): MIT Press. In press

Zweifel P, Ferrari M. Is there a Sisyphus syndrome in health care? In: Zweifel P, Frech III HE, editors. Health economics worldwide. Amsterdam: Kluwer Academic Publishers, 1992: 311–30CrossRef

Hadley J. Medicare spending and mortality rates of the elderly. Inquiry 1988 Winter; 25 (4): 485–93PubMed

Babazono A, Hillman AL. A comparison of international health outcomes and health care spending. Int J Technol Assess Health Care 1994; 10 (3): 376–81PubMedCrossRef

Lichtenberg, FR. Sources of U.S. longevity increase, 1960–1997, National Bureau of Economic Research [NBER] working paper, Cambridge, MA, November 2000

Pindyck RS, Rubinfeld DL. Econometric models and economic forecasts. 4th ed. Boston (MA): Irwin McGraw-Hill, Boston, 1998

10.

Hamilton JD. Time series analysis. Princeton (NJ): Princeton University Press, 1994

11.

Bloomqvist AG, Carter RAL. Is health care really a luxury? J Health Econ 1997; 16 (2): 207–29CrossRef

12.

MacDonald G, Hopkins S. Unit root properties of OECD health care expenditure and GDP data. Health Econ 2002 Jun; 11 (4): 371–6PubMedCrossRef

13.

Cremieux P-Y, P Ouellette, M-C Meilleur, S Leong, P Greenberg, H Birnbaum, Pharmacetical Spending and Health Outcome in the United States, Investing in Health: The Social and Economic Benefits of Health Care Innovation 2001; 14: 59–75CrossRef

14.

Or Z. Exploring the Effects of Health Care on Mortality Across OECD Countries. OECD Labor Market and Social Policy Occasional Papers No. 46, 2000

15.

Or Z. Determinants of Health Outcomes in Industrialized Countries: A Pooled, Cross-country, Time-series Analysis. OECD Economic Studies 2000; No. 30: 53–77

16.

Organisation for Economic Cooperation and Development. Health at a Glance: OECD Indicators 2003: Chart 8. Increasing Obesity Rates Among the Adult Population in OECD Countries. OECD website. www.oecd.org/dataoecd/19/20/16361656.xls. Last accessed December 2003

17.

Hill, JO, JC Peters. Environmental Contributions to the Obesity Epidemic. Science 1998; 280 (5368) May 29: 1371–1374PubMedCrossRef

18.

Winslow R, Peter Landers. Rising Global Obesity Reflects Changes in Diet and Lifestyles, Wall Street Journal 2002; July 1

19.

McGinnis JM, WH. Foege. Actual Causes of Death in the United States, JAMA, Journal of the American Medical Association 1993; 270 (18) Nov. 10: 2207–2213CrossRef

20.

Sturm R. The Effects of Obesity, Smoking and Drinking on Medical Problems and Costs, Health Affairs 2002; 21 (2) (March/April): 245–253PubMedCrossRef

21.

Philipson TJ, RA Posner. The Long-Run Growth of Obesity as a Function of Technological Change, unpublished paper, University of Chicago, Harris School of Public Policy, 1999

22.

Peltzman, S. Offsetting Behavior and Medical Breakthroughs, George J. Stigler Center for the Study of the Economy and the State, University of Chicago, Working Paper No. 169, 2001

23.

Smith, T. Obesity and Nature’s Thumbprint: How Modern Waistlines Can Inform Economic Theory, unpublished paper, Economics Department, University of California, Santa Barbara, 2001

24.

Lichtenberg, FR. Are The Benefits of Newer Drugs Worth Their Cost? Evidence from the 1996 MEPS, Health Affairs 2001; 20 (5) (September/October): 241–251

25.

Lichtenberg, FR. Pharmaceutical Innovation, Mortality Reductions, and Economic Growth. In The Value of Medical Research, KM Murphy and R Topel editors. Chicago: University of Chicago Press, 2003: 74–109

26.

World Health Organization. WHO Mortality Database. WHO website.www3.who.int/whosis/menu.cfm?path=whosis,whsa&language=english. Last accessed December 2003

27.

Organization for Economic Cooperation and Development. OECD Health Data 2000. Paris: OECD

28.

Cutler DM, M McClellan. Is Technological Change in Medical Care Worth it? Health Affairs 2001; 20 (5) (September/ October): 11–29CrossRef

29.

Nordhaus WD. The Health of Nations: The Contribution of Improved Health to Living Standards. In The Value of Medical Research, KM Murphy and R Topel editors. Chicago: University of Chicago Press, 2003: 9–40

30.

Cutler DM, E Richardson. Measuring the Health of the U.S. Population, Brookings Papers on Economic Activity: Microeconomics (1997): 217–271

Title: The effects of pharmaceutical consumption and obesity on the quality of life in the Organization of Economic Cooperation and Development (OECD) countries
Authors: H. E. Frech III
Richard D. Miller Jr
Publication date: 01-10-2004
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue Special Issue 2/2004
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200422002-00004

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The effects of pharmaceutical consumption and obesity on the quality of life in the Organization of Economic Cooperation and Development (OECD) countries

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2004

The economics of follow-on drug research and development

Changes in the costs of treating mental health disorders

Foreword

The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovation

The policy implications of gender mainstreaming for healthcare research in the EU

Impediments to the diffusion of innovative medicines in Europe